Fundamentals Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Share Market News
Osprey (ASX:OSP) share price rises on distribution agreement
Osprey Medical share price shoots 8% higher after product approval
Share Market News
Osprey Medical inks new deal with GE Healthcare
These 3 ASX small caps zoomed higher today
These 3 small cap shares have surged higher today
No profit for Osprey Medical Inc but it's primed for growth
4 ASX stocks sinking today
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
|Mr Mike McCormick||Executive DirectorChief Executive OfficerPresident||Mar 2010||
Mr McCormick has more than 30 years of experience in the medical device industry and President level experience with both public and private medical device companies. Prior to Osprey Medical, he was President/CEO of Anulex Technologies, Inc., focused on supporting the healing of spinal soft tissues; President of Centerpulse Spine-Tech and was involved in the successful sale of Centerpulse Inc. to Zimmer in 2003 for US$3.2 billion. Mike also spent 10 years in sales and sales leadership positions with Boston Scientific's Cardiovascular Division (SCIMED) and Baxter Healthcare.
|Dr Christopher Dean Nave||Non-Executive Director||Oct 2005||
Dr Nave is a founding partner of Brandon Capital Partners and Chief Executive Officer of the Medical Research Commercialisation Fund. Brandon Capital Partners Pty Limited is the investment manager of various funds which have a substantial security holding in the Company. Dr Nave was previously Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia, where he led the commercialization of technologies developed at the Baker and Alfred Hospital. Dr Nave was also Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. In 2014, Dr Nave was awarded the Australian Biotechnology Johnson & Johnson Industry Leadership Award, for his contribution to the industry. Dr Nave is currently a Director of Global Kinetics Corporation, PolyActiva, OccuRx Therapeutics, QueOncology, Azura Ophthalmics and EBR Systems Inc.
|Mr John Erb||Non-Executive ChairmanNon-Executive Director||Jun 2007||
Mr Erb has over 40 years of experience in the medical device industry. He is currently Chairman of the Board and Chief Executive Officer of CHF Solutions, Inc., a manufacturer of medical devices for the heart failure market. John previously served as Chairman of the Board for Vascular Solutions, Inc., manufacturer of medical devices for the cardiology and interventional radiology markets, which was acquired in 2017 by Teleflex, Inc. for US$1 billion. He has held numerous board positions, including CryoCath Technologies, Inc., acquired by Medtronic for US$350 million in 2008; and SenoRx, Inc., acquired by C.R. Bard for US$250 million in 2010.
|Mr Steven Brandt||Non-Executive Director||Jul 2021||
Mr Brandt has over 35 years of experience in the healthcare field. Steven holds over 10 years' experience as acting Vice President for Thoratec Corporation where he managed the expansion of global revenue and the eventual acquisition by St. Jude Medical. Steven also held senior positions at CHF Solutions, St. Jude Medical and XRT Corporation (formerly Interventional Innovations). He has served on the board for Vascular Solutions, Inc. and currently sits on the board for Nuwellis, Inc.
|Mr Martin J Emerson||Non-Executive Director||Aug 2021||
Mr Emerson has over 35 years of experience in the healthcare field. Mr Emerson also has knowledge in market development, geographic expansion and existing market growth. Mr Emerson's experience in healthcare include CEO positions in companies such as American Medical Systems, Galil Medical and his current position as the President and CEO of Monteris Medical. Mr Emerson also has leadership experience in guiding organizations through commercial execution and value creation.
|Mr Brendan Case||Company Secretary||
|Nancy Ness||Chief Financial Officer||
|Brendan Case||Company Secretary||
|Doug Schoenberg||VP Marketing Education & Reimbursement||
|Melanie Hess||VP of Regulatory Affairs Quality Clinical & Compliance||
|Vic Fabano||VP Operations||
|Rod Houfburg||VP Research & Development||
|MRCF3 Services (H) Pty Ltd||7,021,450||27.36%|
|MRCF3 Services (Sw) Pty Ltd||4,228,500||16.48%|
|MRCF3 Services (Hp) Pty Ltd||2,368,912||9.23%|
|Citicorp Nominees Pty Limited||716,425||2.79%|
|J P Morgan Nominees Australia Pty Limited||569,624||2.22%|
|Mr Tianyu Zhu||543,079||2.12%|
|Hsbc Custody Nominees (Australia) Limited||407,429||1.59%|
|Mr Ligang Zhu||399,939||1.56%|
|MRCF3 Services (As) Pty Ltd||343,021||1.34%|
|National Nominees Limited||215,536||0.84%|
|Dixson Trust Pty Limited||200,000||0.78%|
|Paul Mccarthy Nominees Pty Limited <Pma Super Fund A/C>||200,000||0.78%|
|Mr Bahram Rezaei||164,000||0.64%|
|Bnp Paribas Nominees Pty Ltd||157,677||0.61%|
|78 Quarry Road Pty Ltd <David Fergusson Family A/C>||150,000||0.58%|
|Havenranch Pty Limited <Racklyeft Ret Fund Account>||137,171||0.53%|
|Mr Amirpoya Erbezin Zanjani||136,000||0.53%|
|Sacavic Pty Ltd <Morris Super Fund A/C>||120,000||0.47%|
|Bbf1 Iif Partnership Lp||108,422||0.42%|
|Cappafield Pty Ltd <Cappafield Super A/C>||100,000||0.39%|
|Mr Steven Rubic||100,000||0.39%|
|N B T Pty Ltd <Astor Super Fund A/C>||97,000||0.38%|